Towercrest Capital Management Has $383,000 Position in Pfizer Inc. (NYSE:PFE)

Towercrest Capital Management lifted its holdings in Pfizer Inc. (NYSE:PFEFree Report) by 21.8% in the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 13,318 shares of the biopharmaceutical company’s stock after buying an additional 2,382 shares during the period. Towercrest Capital Management’s holdings in Pfizer were worth $383,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also modified their holdings of PFE. Confluence Wealth Services Inc. grew its holdings in shares of Pfizer by 0.5% during the 3rd quarter. Confluence Wealth Services Inc. now owns 65,053 shares of the biopharmaceutical company’s stock valued at $2,158,000 after acquiring an additional 342 shares in the last quarter. Carr Financial Group Corp boosted its position in Pfizer by 3.3% during the third quarter. Carr Financial Group Corp now owns 11,012 shares of the biopharmaceutical company’s stock valued at $344,000 after purchasing an additional 355 shares during the last quarter. Advisor OS LLC grew its stake in Pfizer by 1.0% in the fourth quarter. Advisor OS LLC now owns 35,202 shares of the biopharmaceutical company’s stock valued at $1,013,000 after purchasing an additional 365 shares in the last quarter. Safeguard Investment Advisory Group LLC increased its position in Pfizer by 3.9% in the 4th quarter. Safeguard Investment Advisory Group LLC now owns 9,987 shares of the biopharmaceutical company’s stock worth $288,000 after purchasing an additional 371 shares during the last quarter. Finally, Cairn Investment Group Inc. raised its stake in shares of Pfizer by 5.4% during the 3rd quarter. Cairn Investment Group Inc. now owns 7,323 shares of the biopharmaceutical company’s stock worth $243,000 after purchasing an additional 372 shares in the last quarter. Hedge funds and other institutional investors own 68.36% of the company’s stock.

Pfizer Price Performance

Shares of PFE stock traded down $0.28 during trading hours on Friday, hitting $28.64. 26,106,406 shares of the company’s stock were exchanged, compared to its average volume of 45,219,300. The stock’s 50-day moving average is $27.20 and its 200-day moving average is $28.03. The company has a debt-to-equity ratio of 0.66, a current ratio of 1.05 and a quick ratio of 0.78. Pfizer Inc. has a 52 week low of $25.20 and a 52 week high of $40.37. The stock has a market cap of $162.29 billion, a price-to-earnings ratio of -477.25, a price-to-earnings-growth ratio of 1.22 and a beta of 0.63.

Pfizer (NYSE:PFEGet Free Report) last issued its quarterly earnings results on Wednesday, May 1st. The biopharmaceutical company reported $0.82 earnings per share for the quarter, beating analysts’ consensus estimates of $0.56 by $0.26. Pfizer had a negative net margin of 0.56% and a positive return on equity of 8.64%. The business had revenue of $14.88 billion during the quarter, compared to analyst estimates of $13.87 billion. During the same quarter last year, the business posted $1.23 earnings per share. Pfizer’s revenue for the quarter was down 19.5% compared to the same quarter last year. As a group, research analysts forecast that Pfizer Inc. will post 2.39 EPS for the current year.

Pfizer Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Friday, June 14th. Stockholders of record on Friday, May 10th will be given a dividend of $0.42 per share. This represents a $1.68 annualized dividend and a dividend yield of 5.87%. The ex-dividend date is Thursday, May 9th. Pfizer’s dividend payout ratio is -2,799.53%.

Analyst Upgrades and Downgrades

Several equities analysts have commented on PFE shares. Argus downgraded Pfizer from a “buy” rating to a “hold” rating in a report on Friday, March 22nd. Guggenheim assumed coverage on shares of Pfizer in a report on Friday, February 23rd. They set a “buy” rating and a $36.00 price target for the company. BMO Capital Markets reiterated an “outperform” rating and issued a $36.00 price objective (up from $33.00) on shares of Pfizer in a research note on Thursday, May 2nd. Cantor Fitzgerald reissued an “overweight” rating and set a $45.00 price objective on shares of Pfizer in a research report on Monday, April 15th. Finally, Morgan Stanley raised their target price on Pfizer from $28.00 to $29.00 and gave the company an “equal weight” rating in a report on Thursday, May 2nd. Ten research analysts have rated the stock with a hold rating and six have issued a buy rating to the company’s stock. Based on data from MarketBeat, Pfizer currently has a consensus rating of “Hold” and a consensus price target of $35.86.

Read Our Latest Analysis on PFE

Pfizer Profile

(Free Report)

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.

See Also

Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFEFree Report).

Institutional Ownership by Quarter for Pfizer (NYSE:PFE)

Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.